What is Relmada Therapeutics, Inc.'s intangibles (net)?

Relmada Therapeutics, Inc. (RLMD) reported intangibles (net) of $3.54M in Q4 2025.

What is the long-term trend for Relmada Therapeutics, Inc.'s intangibles (net)?

Over 2 years (2023 to 2025), Relmada Therapeutics, Inc.'s intangibles (net) has grown at a 16.7% compound annual growth rate (CAGR), from $2.6M to $3.54M.

What does intangibles (net) mean?

Identifiable intangible assets (patents, trademarks, customer relationships, technology) net of accumulated amortization — excluding goodwill.

Relmada Therapeutics, Inc. RLMD Intangibles (Net)

Intangibles (Net) at other companies

CG OncologyCGON

$560K—

Nuvation BioNUVB

$10.76M+144%

Zevra Therapeutics, Inc.ZVRA

$6.11M-90.9%

XER

Xeris Biopharma Holdings, Inc.XERS

$85.37M-11.3%

Rigel PharmaceuticalsRIGL

$24.16M—

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

See full

Operating income-$19.5M-6.8%

Net income-$19.1M-8.5%

EPS (diluted)-$0.22+62.1%

Balance sheet

See full

Cash & equivalents$9.8M+750%

Total debt$104.1M-40.4%

Total equity$218.7M+875%

Total assets$235.4M+750%

Cash flow

See full

Operating cash flow-$15.1M+16.6%

Valuation

See full

Market cap$677.17M+2,907%

Returns & leverage

See full

Return on equity-48.8%-20.0pp

Debt / equity0.9×0.0×

Current ratio18.3×+13.0×

Where this comes from

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets.

The official record: Relmada Therapeutics, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relmada Therapeutics, Inc.'s intangibles (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Relmada Therapeutics, Inc.'s intangibles (net)?: Relmada Therapeutics, Inc. (RLMD) reported intangibles (net) of $3.54M in Q4 2025.
What is the long-term trend for Relmada Therapeutics, Inc.'s intangibles (net)?: Over 2 years (2023 to 2025), Relmada Therapeutics, Inc.'s intangibles (net) has grown at a 16.7% compound annual growth rate (CAGR), from $2.6M to $3.54M.
What does intangibles (net) mean?: Identifiable intangible assets (patents, trademarks, customer relationships, technology) net of accumulated amortization — excluding goodwill.